These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24174884)

  • 1. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.
    Thurman AR; Clark MR; Hurlburt JA; Doncel GF
    Int J Womens Health; 2013 Oct; 5():695-708. PubMed ID: 24174884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
    Smith JM; Moss JA; Srinivasan P; Butkyavichene I; Gunawardana M; Fanter R; Miller CS; Sanchez D; Yang F; Ellis S; Zhang J; Marzinke MA; Hendrix CW; Kapoor A; Baum MM
    PLoS One; 2017; 12(10):e0185946. PubMed ID: 28982161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
    Friend DR
    Expert Opin Drug Deliv; 2012 Apr; 9(4):417-27. PubMed ID: 22385316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
    Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
    PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multipurpose prevention technologies: products in development.
    Friend DR; Clark JT; Kiser PF; Clark MR
    Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.
    Friend DR
    Drug Deliv Transl Res; 2011 Jun; 1(3):185-93. PubMed ID: 25788239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
    Mugo NR; Mudhune V; Heffron R; Thomas KK; McLellan-Lemal E; Njoroge B; Peacock S; O'Connor SM; Nyagol B; Ouma E; Ridzon R; Wiener J; Isoherranen N; Erikson DW; Ouattara LA; Yousefieh N; Jacot TA; Haaland RE; Morrison SA; Haugen HS; Thurman AR; Allen SA; Baeten JM; Samandari T; Doncel GF
    Front Reprod Health; 2023; 5():1118030. PubMed ID: 37383290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
    Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
    PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
    PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
    Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intravaginal ring for the sustained delivery of antibodies.
    Gunawardana M; Baum MM; Smith TJ; Moss JA
    J Pharm Sci; 2014 Nov; 103(11):3611-3620. PubMed ID: 25231193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic.
    Tolley EE; Zissette S; Taylor J; Hanif H; Ju S; Schwarz J; Thurman A; Tyner D; Brache V; Doncel GF
    J Womens Health (Larchmt); 2022 Sep; 31(9):1343-1352. PubMed ID: 35363574
    [No Abstract]   [Full Text] [Related]  

  • 16. Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.
    Young IC; Srinivasan P; Shrivastava R; Janusziewicz R; Thorson A; Cottrell ML; Sellers RS; Sykes C; Schauer A; Little D; Kelley K; Kashuba ADM; Katz D; Pyles RB; García-Lerma JG; Vincent KL; Smith J; Benhabbour SR
    Biomaterials; 2023 Oct; 301():122260. PubMed ID: 37549505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019.
    McLellan-Lemal E; Deaton SR; Betts JE; Ondenge K; Mudhune V; O'Connor SM; Nyagol B; Thurman AR; Doncel GF; Allen SA; Heffron R; Mugo NR;
    Contemp Clin Trials; 2022 Nov; 122():106935. PubMed ID: 36162740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
    PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.
    Ugaonkar SR; Wesenberg A; Wilk J; Seidor S; Mizenina O; Kizima L; Rodriguez A; Zhang S; Levendosky K; Kenney J; Aravantinou M; Derby N; Grasperge B; Gettie A; Blanchard J; Kumar N; Roberts K; Robbiani M; Fernández-Romero JA; Zydowsky TM
    J Control Release; 2015 Sep; 213():57-68. PubMed ID: 26091920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Hormonal Intravaginal Rings: Technology and Challenges.
    Rafiei F; Tabesh H; Farzad S; Farzaneh F; Rezaei M; Hosseinzade F; Mottaghy K
    Geburtshilfe Frauenheilkd; 2021 Jul; 81(7):789-806. PubMed ID: 34276064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.